These biopharma stocks have great prospects and can be purchased today at attractive prices.
News & Analysis: Parexel International
The company notified the SEC that it will be filing its quarterly report late after errors were discovered, but it may not be as bad as it appears.
Find out whether this is a case of a temporarily broken stock or a broken business model.
Contract research organizations Quintiles (Q), Icon PLC (ICLR), Covance (CVD), and Parexel (PRXL) are redefining how biopharma discovers and develops new therapies.
Contract Researchers have taken it on the chin following Parexel's (PRXL) lackluster quarterly results. But that view might be short sighted given drug makers are increasingly turning to CROs to usher drugs through trials.
Here are two stocks our analysts will be watching closely this week. Will you be watching too?
The top business stories on JPMorgan, Home Depot and Best Buy for today's Foolish investor.
PAREXEL meets Wall Street's lofty profit expectations, but is derailed by its fifth quarterly decline in another key metric.
Keep your eye on margins.
Look here for a clue.